Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has been assigned a consensus rating of “Hold” from the twenty-five brokerages that are presently covering the company, Marketbeat reports. Five investment analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have assigned a buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $130.88.
A number of research firms have recently issued reports on ICPT. Seaport Global Securities reiterated a “buy” rating and issued a $136.00 target price on shares of Intercept Pharmaceuticals in a research note on Friday, October 6th. JMP Securities reiterated an “outperform” rating and issued a $140.00 target price (down previously from $150.00) on shares of Intercept Pharmaceuticals in a research note on Tuesday, September 26th. Jefferies Group reiterated a “buy” rating and issued a $275.00 target price on shares of Intercept Pharmaceuticals in a research note on Wednesday, September 20th. BidaskClub cut shares of Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th. Finally, Citigroup set a $74.00 target price on shares of Intercept Pharmaceuticals and gave the company a “hold” rating in a research note on Thursday, December 21st.
A number of hedge funds have recently bought and sold shares of the stock. FMR LLC raised its position in Intercept Pharmaceuticals by 0.7% in the 2nd quarter. FMR LLC now owns 3,750,678 shares of the biopharmaceutical company’s stock worth $454,094,000 after purchasing an additional 25,958 shares during the last quarter. Carmignac Gestion raised its position in Intercept Pharmaceuticals by 0.4% in the 2nd quarter. Carmignac Gestion now owns 2,035,592 shares of the biopharmaceutical company’s stock worth $246,449,000 after purchasing an additional 7,400 shares during the last quarter. Vanguard Group Inc. raised its position in Intercept Pharmaceuticals by 4.5% in the 2nd quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock worth $160,797,000 after purchasing an additional 57,149 shares during the last quarter. Senvest Management LLC bought a new position in Intercept Pharmaceuticals in the 3rd quarter worth approximately $33,883,000. Finally, First Trust Advisors LP raised its position in Intercept Pharmaceuticals by 4.5% in the 3rd quarter. First Trust Advisors LP now owns 300,455 shares of the biopharmaceutical company’s stock worth $17,438,000 after purchasing an additional 13,044 shares during the last quarter. Hedge funds and other institutional investors own 73.76% of the company’s stock.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.48) by $0.59. Intercept Pharmaceuticals had a negative net margin of 344.74% and a negative return on equity of 176.51%. The company had revenue of $41.33 million during the quarter, compared to analysts’ expectations of $36.95 million. During the same quarter in the previous year, the company posted ($3.59) earnings per share. Intercept Pharmaceuticals’s quarterly revenue was up 697.9% compared to the same quarter last year. equities research analysts predict that Intercept Pharmaceuticals will post -13.36 EPS for the current fiscal year.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.